Paul W H I Parren
Overview
Explore the profile of Paul W H I Parren including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
154
Citations
9447
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
King L, Veth M, Iglesias-Guimarais V, Blijdorp I, Kloosterman J, Vis A, et al.
iScience
. 2024 Dec;
27(12):111289.
PMID: 39628574
Vγ9Vδ2 T cells constitute a homogeneous effector T cell population that lyses tumors of different origin, including the prostate. We generated a bispecific T cell engager (bsTCE) to direct Vγ9Vδ2...
2.
3.
Wang H, van de Bovenkamp F, Dijkstra D, Abendstein L, Borggreven N, Pool J, et al.
Front Immunol
. 2024 May;
15:1288597.
PMID: 38817607
Complement activation protects against infection but also contributes to pathological mechanisms in a range of clinical conditions such as autoimmune diseases and transplant rejection. Complement-inhibitory drugs, either approved or in...
4.
Dijkstra D, van de Bovenkamp F, Abendstein L, Zuijderduijn R, Pool J, Kramer C, et al.
Proc Natl Acad Sci U S A
. 2023 Dec;
120(50):e2310666120.
PMID: 38048459
Autoantibodies directed against complement component C1q are commonly associated with autoimmune diseases, especially systemic lupus erythematosus. Importantly, these anti-C1q autoantibodies are specific for ligand-bound, solid-phase C1q and do not bind...
5.
van der Wulp W, Remst D, Kester M, Hagedoorn R, Parren P, van Kasteren S, et al.
Cancer Gene Ther
. 2023 Nov;
31(1):58-68.
PMID: 37945970
Antibody-mediated delivery of immunogenic epitopes to redirect virus-specific CD8 T-cells towards cancer cells is an emerging and promising new therapeutic strategy. These so-called antibody-epitope conjugates (AECs) rely on the proteolytic...
6.
King L, Toffoli E, Veth M, Iglesias-Guimarais V, Slot M, Amsen D, et al.
Cancer Immunol Res
. 2023 Jun;
11(9):1237-1252.
PMID: 37368791
Vγ9Vδ2 T cells are effector cells with proven antitumor efficacy against a broad range of cancers. This study aimed to assess the antitumor activity and safety of a bispecific antibody...
7.
van der Wulp W, Gram A, Bleijlevens B, Hagedoorn R, Araman C, Kim R, et al.
Front Immunol
. 2023 Jun;
14:1183914.
PMID: 37261346
Therapeutic antibody-epitope conjugates (AECs) are promising new modalities to deliver immunogenic epitopes and redirect virus-specific T-cell activity to cancer cells. Nevertheless, many aspects of these antibody conjugates require optimization to...
8.
Lameris R, Ruben J, Iglesias-Guimarais V, de Jong M, Veth M, van de Bovenkamp F, et al.
Cell Rep Med
. 2023 Mar;
4(3):100961.
PMID: 36868236
Bispecific T cell engagers (bsTCEs) hold great promise for cancer treatment but face challenges due to the induction of cytokine release syndrome (CRS), on-target off-tumor toxicity, and the engagement of...
9.
Oostindie S, Lazar G, Schuurman J, Parren P
Nat Rev Drug Discov
. 2022 Jul;
21(10):715-735.
PMID: 35790857
Antibodies are the cardinal effector molecules of the immune system and are being leveraged with enormous success as biotherapeutic drugs. A key part of the adaptive immune response is the...
10.
Saura-Esteller J, de Jong M, King L, Ensing E, Winograd B, de Gruijl T, et al.
Front Immunol
. 2022 Jul;
13:915837.
PMID: 35784326
γδ T-cells directly recognize and kill transformed cells independently of HLA-antigen presentation, which makes them a highly promising effector cell compartment for cancer immunotherapy. Novel γδ T-cell-based immunotherapies, primarily focusing...